RhumbLine Advisers
ZBIO

RhumbLine Advisers’s Zenas BioPharma ZBIO Stock Holding History

RhumbLine Advisers’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$869K Buy
34,245
+7,432
+28% +$148K ﹤0.01% 2406
2026
Q1 		$524K Buy
26,813
+4,867
+22% +$109K ﹤0.01% 2583
2025
Q4 		$797K Buy
21,946
+732
+3% +$24.1K ﹤0.01% 2365
2025
Q3 		$471K Buy
21,214
+1,493
+8% +$24.3K ﹤0.01% 2736
2025
Q2 		$191K Buy
19,721
+8,207
+71% +$79.9K ﹤0.01% 3249
2025
Q1 		$91K Sell
11,514
-27,428
-70% -$215K ﹤0.01% 3418
2024
Q4 		$319K Buy
+38,942
New +$607K ﹤0.01% 2956

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RhumbLine Advisers's ZBIO Position: Q2 2026 in Review

RhumbLine Advisers increased its Zenas BioPharma (ZBIO) stake by 28% in Q2 2026, buying an estimated $148K and bringing the position to 34,245 shares worth $869K. The position accounts for ﹤0.01% of the portfolio, ranked #2406.

RhumbLine Advisers first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • RhumbLine Advisers held 34,245 shares of Zenas BioPharma worth $869K as of Q2 2026.
  • RhumbLine Advisers bought 7,432 Zenas BioPharma shares in Q2 2026, an estimated $148K.
  • Zenas BioPharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2406 holding.
  • RhumbLine Advisers first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.